[1]
|
Gillman, P.K. (2010) Neuroleptic Malignant Syndrome: Mechanisms, Interactions, and Causality. Movement Disorders, 25, 1780-1790. http://dx.doi.org/10.1002/mds.23220
|
[2]
|
Wappler, F. (2001) Malignant Hyperthermia. European Journal of Anaesthesiology, 18, 632-652. http://dx.doi.org/10.1046/j.1365-2346.2001.00888.x
|
[3]
|
Musselman, M.E. and Saely, S. (2013) Diagnosis and Treatment of Drug-Induced Hyperthermia. American Journal of Health-System Pharmacy, 70, 34-42. http://dx.doi.org/10.2146/ajhp110543
|
[4]
|
Eyer, F. and Zilker, T. (2007) Bench to Bedside Review: Mechanisms and Management of Hyperthermia Due to Toxicity. Critical Care, 11, 236. http://dx.doi.org/10.1186/cc6177
|
[5]
|
McAllen, K.J. and Schwartz, D.R. (2010) Adverse Drug Reactions Resulting in Hyperthermia in the Intensive Care Unit. Critical Care Medicine, 38, 244-252. http://dx.doi.org/10.1097/CCM.0b013e3181dda0d4
|
[6]
|
Boyer, E.W. and Shannon, M. (2005) The Serotonin Syndrome. The New England Journal of Medicine, 352, 1112-1120. http://dx.doi.org/10.1056/NEJMra041867
|
[7]
|
Lefkowitz, D., Ford, C.S., Rich, C., Biller, J. and McHenry Jr., L.C. (1938) Cerebellar Syndrome Following Neuroleptic Induced Heat Stroke. Journal of Neurology Neurosurgery and Psychiatry, 46, 183-185. http://dx.doi.org/10.1136/jnnp.46.2.183
|
[8]
|
Hadad, E., Weinbroum, A.A. and Ben-Abraham, R. (2003) Drug Induced Hyperthermia and Muscle Rigidity: A Practical Approach. European Journal of Emergency Medicine, 10, 149-154. http://dx.doi.org/10.1097/00063110-200306000-00018
|
[9]
|
Adnet, P., Levstavel, P. and Krivosic-Horber, R. (2000) Neuroleptic Malignant Syndrome. British Journal of Anaesthesia, 85, 129-135. http://dx.doi.org/10.1093/bja/85.1.129
|
[10]
|
Denborough, M.A. (1982) Heat Stroke and Malignant Hyperpyrexia. The Medical Journal of Australia, 1, 204-205.
|
[11]
|
Meyers, E.F. and Meyers, R.W. (1982) Thermic Stress Syndrome. JAMA, 247, 2098-2099. http://dx.doi.org/10.1001/jama.1982.03320400018018
|
[12]
|
Strawn, J.R., Keck, P.E. and Caroff, S.N. (2007) Neuroleptic Malignant Syndrome. American Journal of Psychiatry, 164, 870-876. http://dx.doi.org/10.1176/ajp.2007.164.6.870
|
[13]
|
Grunau, B.E., Wiens, M.O. and Brubacher, J.R. (2010) Dantrolene in the Treatment of MDMA-Related Hyperpyrexia: A Systematic Review. Canadian Journal of Emergency Medicine, 12, 435-442.
|
[14]
|
Kurz, A. (2008) Physiology of Thermoregulation. Best Practice & Research Clinical Anaesthesiology, 22, 627-644. http://dx.doi.org/10.1016/j.bpa.2008.06.004
|
[15]
|
Krause, T., Gerbershagen, M.U., Fiege, M., Weibhorn, R. and Wappler, F. (2004) Dantrolene—A Review of Its Pharmacology, Therapeutic Use and New Developments. Anaesthesia, 59, 364-373.
|
[16]
|
Rosenberg, H., Davis, M., James, D., Pollock, N. and Stowell, K. (2007) Malignant Hyperthermia. Orphanet Journal of Rare Diseases, 2, 21. http://dx.doi.org/10.1186/1750-1172-2-21
|
[17]
|
Davis, J.M., Caroff, S.N. and Mann, S.C. (2000) Treatment of Neuroleptic Malignant Syndrome. Psychiatric Annals, 30, 325-331. http://dx.doi.org/10.3928/0048-5713-20000501-10
|
[18]
|
Caroff, S.N. (2003) Neuroleptic Malignant Syndrome. In: Man, S.C., Caroff, S.N., Keck Jr., P.E. and Lazarus, A., Eds., Neuroleptic Malignant Syndrome and Related Conditions, 2nd Edition, American Psychiatric Publishing, Washington, DC, 1-44.
|
[19]
|
Shalev, A., Hermesh, H. and Munitz, H. (1989) Mortality from Neuroleptic Malignant Syndrome. Journal of Clinical Psychiatry, 50, 18-25.
|
[20]
|
Reulbach, U., Dutsch, C., Biermann, T., Sperling, W., Thuerauf, N., Kornhuber, J. and Bleich, S. (2007) Managing an Effective Treatment for Neuroleptic Malignant Syndrome. Critical Care, 11, R4.
|
[21]
|
Rosebush, R.L., Stewart, T. and Mazurek, M.F. (1991) The Treatment of Neuroleptic Malignant Syndrome. Are Dantrolene and Bromocriptine Useful Adjuncts to Supportive Care? British Journal of Psychiatry, 159, 709-712. http://dx.doi.org/10.1192/bjp.159.5.709
|
[22]
|
Ginz, H.F., Levano, S., Girard, T., Urwyler, A. and Hamel, C. (2012) Dantrolene for Severe Rhabdomyolysis in Staphylococcus aureus Toxic Shock Syndrome. European Journal of Anaesthesiology, 29, 161-162. http://dx.doi.org/10.1097/EJA.0b013e32834c7c9d
|
[23]
|
Levenson, J.L. (1985) Neuroleptic Malignant Syndrome. American Journal of Psychiatry, 142, 1137-1145. http://dx.doi.org/10.1176/ajp.142.10.1137
|
[24]
|
ACCP/SCCM (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions of Sepsis and Organ Failure and Guidelines for the Use on Innovative Therapies in Sepsis. Critical Care Medicine, 20, 864-874. http://dx.doi.org/10.1097/00003246-199206000-00025
|
[25]
|
Sachdev, P.S. (2005) A Rating Scale for Neuroleptic Malignant Syndrome. Psychiatry Research, 135, 249-256. http://dx.doi.org/10.1016/j.psychres.2005.05.003
|
[26]
|
Nisijima, K. and Shioda, K. (2013) Temporal Changes in Serum Creatine Kinase Concentration and Degree of Muscle Rigidity in 24 Patients with Neuroleptic Malignant Syndrome. Neuropsychiatric Disease and Treatment, 9, 853-859. http://dx.doi.org/10.2147/NDT.S45084
|
[27]
|
Rosenberg, M.R. and Green, M. (1989) Neuroleptic Malignant Syndrome. Review of Response to Therapy. JAMA Internal Medicine, 149, 1927-1931. http://dx.doi.org/10.1001/archinte.1989.00390090009002
|
[28]
|
Sakkas, P., Davis, J.M., Janicak, P.G. and Wang, Z.Y. (1991) Drug Treatment of the Neuroleptic Malignant Syndrome. Psychopharmacology Bulletin, 27, 381-384.
|
[29]
|
Hollander, A.S., Olney, R.C., Blackett, P.R. and Marshall, B.A. (2003) Fatal Malignant Hyperthermia Like Syndrome with Rhabdomyolysis Complicating the Presentation of Diabetes Mellitus in Adolescent Males. Pediatrics, 111, 1447-1452. http://dx.doi.org/10.1542/peds.111.6.1447
|
[30]
|
Morales, A.E. and Rosenbloom, A.L. (2004) Death Caused by Hyperglycemic Hyperosmolar State at the Onset of Type 2 Diabetes. Journal of Pediatrics, 144, 270-273. http://dx.doi.org/10.1016/j.jpeds.2003.10.061
|
[31]
|
Carchman, R.M., Dechert-Zeger, M., Calikoglu, A.S. and Harris, B.D. (2005) A New Challenge in Pediatric Obesity: Pediatric Hyperglycemic Hyperosmolar Syndrome. Pediatric Critical Care Medicine, 6, 20-24. http://dx.doi.org/10.1097/01.PCC.0000149134.61673.77
|
[32]
|
Kilbane, B.J., Mehta, S., Backeljauw, P.F., Shanley, T.P. and Crimmins, N.A. (2006) Approach to Management of Malignant Hyperthermia-Like Syndrome in Pediatric Diabetes Mellitus. Pediatric Critical Care Medicine, 7, 169-173. http://dx.doi.org/10.1097/01.PCC.0000192340.09136.82
|
[33]
|
Hotchkiss, R.S. and Karl, I.E. (1994) Dantrolene Ameliorates the Metabolic Hallmarks of Sepsis in Rats and Improves Survival in a Mouse Model of Endotoxemia. Proceedings of the National Academy of Sciences of the United States of America, 91, 3039-3043. http://dx.doi.org/10.1073/pnas.91.8.3039
|